Deutsche Bank Maintains Buy on Gilead Sciences (GILD) after Strong Hepatitis C Combo Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky weekÂ
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Abbott Laboratories (NYSE: ABT) | Delayed: 103.26 +0.75 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $102.51 | 52 Week High | $46.38 | |||
| Open | $102.28 | 52 Week Low | $36.00 | |||
| Day High | $103.70 | P/E | 68.84 | |||
| Day Low | $101.56 | EPS | $1.50 | |||
| Volume | 3,296,596 | |||||
| Gilead Sciences (NASDAQ: GILD) | Delayed: 157.01 -0.18 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.19 | 52 Week High | $108.63 | |||
| Open | $156.47 | 52 Week Low | $71.39 | |||
| Day High | $157.65 | P/E | 86.75 | |||
| Day Low | $155.76 | EPS | $1.81 | |||
| Volume | 2,513,374 | |||||
